What Do AI Platforms Project About WAINUA’s Future Approvals or Indications?
by WAINUA (eplontersen), developed by Ionis Pharmaceuticals and AstraZeneca, has established itself as an important RNA-targeted therapy for hereditary transthyretin-mediated amyloidosis with polyneuropathy (ATTRv-PN). But the …